Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$11.08 USD
-0.16 (-1.42%)
Updated May 3, 2024 04:00 PM ET
After-Market: $11.08 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PIRS 11.08 -0.16(-1.42%)
Will PIRS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PIRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PIRS
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
PIRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for August 23rd
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
Other News for PIRS
Pieris Pharmaceuticals trading halted, news pending
Pieris Pharmaceuticals OKs 1-for-80 reverse stock split
Pieris Pharmaceuticals announces 1-for-80 reverse stock split
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Pieris Pharmaceuticals Enacts Reverse Stock Split for NASDAQ Compliance